Research Vision:

The prognosis of advanced cancer (e.g. Pancreatic, Colorectal, Esophageal, Gastric, Breast) is still very bad. We are developing novel therapeutics using the oncolytic nature of adenoviruses to improve the prognosis of those cancers, particularly by neoadjuvant therapy to enable surgical resection.

Research Areas:

• Oncolytic adenovirus-based therapeutics

• GI cancers

• Effects of obesity on cancer development

Research Publications:

1. Miura Y, Yamasaki S, Davydova J, Brown E, Aoki K, Vickers S, Yamamoto M. Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library. Mol Ther. 2013 Jan;21(1):139-48. doi: 10.1038/mt.2012.205. Epub 2012 Oct 2. PMID: 23032977; PMCID: PMC3538312.

2. Sato-Dahlman M, Miura Y, Huang JL, Hajeri P, Jacobsen K, Davydova J, Yamamoto M. CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer. Oncotarget. 2017 Jun 2;8(44):76044-76056. doi: 10.18632/oncotarget.18340. PMID: 29100290; PMCID: PMC5652684.

3. Salzwedel AO, Han J, LaRocca CJ, Shanley R, Yamamoto M, Davydova J. Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer. Oncotarget. 2018 Apr 6;9(26):18041-18052. doi: 10.18632/oncotarget.24710. PMID: 29719589; PMCID: PMC5915056.

4. Huang JL, LaRocca CJ, Yamamoto M. Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts. Biomedicines. 2016 Sep 19;4(3):23. doi: 10.3390/biomedicines4030023. PMID: 28536390; PMCID: PMC5344254.

5. Davydova J, Yamamoto M. Oncolytic adenoviruses: design, generation, and experimental procedures. Curr Protoc Hum Genet. 2013 Jul;Chapter 12:Unit 12.14. doi: 10.1002/0471142905.hg1214s78. PMID: 23853080.